UNION Therapeutics Concludes ADESOS Phase 2b Study

UNION Therapeutics A/S (Association), a clinical stage and drug improvement organization focused on immunology, reports effective culmination of the ADESOS stage 2b, randomized, dose finding study assessing orismilast as an oral treatment in 233 patients with moderate-to-extreme AD.

Topline results from the ADESOS review have been chosen for an oral show by the Signatory Investigator, Professor Jonathan Silverberg, MD, PhD, MPH at the late breaking research meetings at Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Gathering on June 8-10, 2024, in Chicago, US. The ADESOS clinical study data will be presented for the first time at this event.

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Signatory Investigator for ADESOS study said:  “AD is one of the most common chronic inflammatory skin diseases worldwide. Innovation in recent years has brought good injectable treatments to patients, but a significant unmet medical need for a safe and effective oral treatment still exists. Orismilast offers the potential for a safe oral treatment with early itch reduction and holds a significant promise as a novel treatment option in AD.”

Kim Kjøller, co-chief executive officer of UNION therapeutics adds: “The results from the ADESOS study with orismilast in atopic dermatitis (AD) follows positive read outs in psoriasis and hidradenitis suppurativa (HS) confirming the potential of orismilast as a safe oral treatment across immunology. We are pleased that the phase 2b results from the ADESOS study have been selected for an oral presentation at the RAVE Conference in Chicago and look forward to the results being shared and discussed with the leading experts in the field.”